BMY-14802
BMY-14802 is a chemical compound that has been studied for its potential pharmacological properties. It is primarily known for its role as a serotonin receptor antagonist, specifically targeting the 5-HT1A receptor.
Chemical Structure and Properties[edit | edit source]
BMY-14802 is classified as a piperazine derivative. The chemical structure of BMY-14802 includes a piperazine ring, which is a common feature in many pharmacologically active compounds. The exact molecular formula and structural details are essential for understanding its interaction with biological targets.
Pharmacology[edit | edit source]
BMY-14802 has been investigated for its effects on the central nervous system. As a 5-HT1A receptor antagonist, it has the potential to influence various neurological and psychiatric conditions. The 5-HT1A receptor is a subtype of the serotonin receptor that plays a crucial role in the modulation of mood, anxiety, and cognition.
Mechanism of Action[edit | edit source]
The primary mechanism of action of BMY-14802 involves the inhibition of the 5-HT1A receptor. By blocking this receptor, BMY-14802 can alter the levels of serotonin in the brain, which may lead to changes in mood and behavior. This mechanism is similar to that of other 5-HT1A receptor antagonists, which are often explored for their potential therapeutic effects in conditions such as depression and anxiety disorders.
Potential Therapeutic Uses[edit | edit source]
Research into BMY-14802 has suggested several potential therapeutic applications. These include:
- Antidepressant effects: By modulating serotonin levels, BMY-14802 may help alleviate symptoms of depression.
- Anxiolytic effects: The compound's action on the 5-HT1A receptor could reduce anxiety.
- Antipsychotic effects: There is potential for BMY-14802 to be used in the treatment of schizophrenia and other psychotic disorders.
Research and Development[edit | edit source]
BMY-14802 is still under investigation, and more research is needed to fully understand its pharmacological profile and therapeutic potential. Clinical trials and preclinical studies are essential to determine its efficacy and safety in humans.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
-
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD